Ozempic, Mounjaro and Wegovy may not be the lightbulb, jet airplane or internet, but their impact is expected to be so ...
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...
More than 15.5 million Americans have tried weight loss injectables, but risks are rising with the proliferation of counterfeit drugs, writes Robin Epley.
Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared ...
In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., ...
Semaglutide (Wegovy and Ozempic): Originally developed for type 2 diabetes, this medication mimics the GLP-1 hormone, ...
A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...